Literature DB >> 2046877

Neurotensin causes a greater increase in the metabolism of dopamine in the accumbens than in the striatum in vivo.

R Rivest1, F B Jolicoeur, C A Marsden.   

Abstract

Differential pulse voltammetry with carbon fibre electrodes was used to study the effect of central administration of neurotensin on the extracellular level of 3,4-dihydroxyphenylacetic acid (DOPAC) in the nucleus accumbens and the striatum in anaesthetised rats. Intracerebroventricular injection of neurotensin (10 micrograms) increased the peak height for DOPAC 20 min after administration in the nucleus accumbens but only after 40 min in the striatum. The maximum increase was similar in both regions, with 30% and 27% above the pre-injection basal level, respectively. Neurotensin (1 micrograms) however increased the extracellular level of DOPAC in the nucleus accumbens alone. Neurotensin (0.1, 1.0 and 3.0 micrograms/0.5 microliter), injected into the ventral tegmental area, induced a potent and long-lasting elevation of the peak height for DOPAC in the nucleus accumbens, while the same doses in the substantia nigra produced effects on the metabolism of dopamine in the striatum of smaller amplitude and shorter duration. The maximum effect of each dose was about 2.5 times greater in the mesolimbic, compared to the nigrostriatal system. Amphetamine (2 mg/kg, s.c.) decreased the extracellular level of DOPAC with a similar magnitude, both in the nucleus accumbens (52%) and the striatum (47%). Intracerebroventricular administration of neurotensin (1 micrograms), 5 min after amphetamine, did not alter the effect of amphetamine on the extracellular level of DOPAC either in the nucleus accumbens or the striatum. However, neurotensin (10 micrograms) partially reversed the effect of amphetamine in the nucleus accumbens and had a similar but smaller and delayed effect in the striatum. The results from the present study, together with previous neurobehavioural studies, suggest that neurotensin has a relatively selective action on the mesolimbic dopaminergic system in the rat.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2046877     DOI: 10.1016/0028-3908(91)90038-d

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine.

Authors:  C Betancur; R Cabrera; E R de Kloet; D Pélaprat; W Rostène
Journal:  Neuropsychopharmacology       Date:  1998-10       Impact factor: 7.853

2.  Correlative ultrastructural distribution of neurotensin receptor proteins and binding sites in the rat substantia nigra.

Authors:  H Boudin; D Pélaprat; W Rostène; V M Pickel; A Beaudet
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

3.  Comparison of the locomotor-activating effects of bicuculline infusions into the preoptic area and ventral pallidum.

Authors:  Daniel S Zahm; Zachary M Schwartz; Heather N Lavezzi; Leora Yetnikoff; Kenneth P Parsley
Journal:  Brain Struct Funct       Date:  2013-02-20       Impact factor: 3.270

4.  Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol.

Authors:  R Rivest; C A Marsden
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

5.  Blockade of neurotensin-induced motor activity by inhibition of protein kinase.

Authors:  P W Kalivas
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

6.  Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats.

Authors:  M Poncelet; J Souilhac; C Gueudet; J P Terranova; D Gully; G Le Fur; P Soubrié
Journal:  Psychopharmacology (Berl)       Date:  1994-10       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.